Farrah C.
About Farrah C.
Farrah C. serves as the Senior Director of CMC Strategic Planning & Operations at Generate Biomedicines, a position she has held since 2022. She has extensive experience in the biopharmaceutical industry, having worked at companies such as Xilio Therapeutics, Shire Pharmaceuticals, Novartis, Lonza, and ImmunoGen, Inc.
Current Role at Generate Biomedicines
Farrah C. serves as the Senior Director of CMC Strategic Planning & Operations at Generate Biomedicines. She has held this position since 2022, contributing to the company's strategic initiatives in the field of biomedicine. Her role involves overseeing the planning and operational aspects of Chemistry, Manufacturing, and Controls (CMC), ensuring that the processes align with the company's objectives.
Previous Experience in Biopharmaceuticals
Farrah C. has a diverse background in the biopharmaceutical industry. She worked at Xilio Therapeutics, Inc. in CMC Operations for one year from 2021 to 2022. Prior to that, she spent seven years at ImmunoGen, Inc. in External Manufacturing from 2010 to 2017. Her experience also includes roles at Novartis in Alliance Management from 2017 to 2019, Shire Pharmaceuticals in Technical Operations from 2007 to 2010, and Lonza in Manufacturing Science and Technology from 2005 to 2007.
Educational Background
Farrah C. holds a Master of Business Administration (MBA) from the D'Amore-McKim School of Business at Northeastern University, where she focused on Supply Chain and International Management. Additionally, she earned a Bachelor of Science (BS) degree in Biology from Northeastern University, providing her with a strong foundation in the life sciences.
Career Timeline
Farrah C.'s career spans multiple roles in the biopharmaceutical sector. She began her career at Lonza from 2005 to 2007, followed by a position at Shire Pharmaceuticals until 2010. Afterward, she joined ImmunoGen, Inc. and worked there until 2017. She then transitioned to Novartis for two years before moving to Xilio Therapeutics, Inc. in 2021. In 2022, she joined Generate Biomedicines, where she continues to advance her career.